By Matteo Castia

 

Shield Therapeutics PLC said Monday that competitor Teva Pharmaceutical Industries Ltd. has withdrawn all its oppositions against the company's patents.

"Teva has withdrawn both its appeal against the European Patent Office's decision with regard to Shield's patent number 2668175, which covers a 'process for preparing an iron hydroxypyrone' and their opposition with regard to Shield's patent number 3160951 which covers 'crystalline forms of ferric maltol," the pharmaceutical company said.

This means that both patents are maintained and will continue to provide protection, Shield said.

 

Write to Matteo Castia at matteo.castia@dowjones.com

 

(END) Dow Jones Newswires

October 19, 2020 02:59 ET (06:59 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Teva Pharmaceutical Indu... Charts.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Teva Pharmaceutical Indu... Charts.